Hypoglycemia and Clinical Outcomes

Hypoglycemia is the most common acute complication of diabetes therapy and has long been considered an unavoidable consequence of glucose-lowering therapy. Accumulating evidence, however, indicates that hypoglycemia is a clinically important event associated with a broad range of adverse outcomes. Severe hypoglycemia has been consistently linked to cardiovascular events and mortality in post hoc analyses of major glucose-lowering trials and in large observational cohorts. It has also been associated with cognitive decline and dementia, falls and fractures, and increased healthcare utilization. Importantly, these risks are not distributed evenly across patients. In older adults, diminished counterregulatory hormone responses and impaired awareness of hypoglycemia increase the frequency of episodes that may progress to severe hypoglycemia without warning symptoms. Reduced physiological reserve, together with the cascade from falls and fractures to functional decline, further magnifies the absolute risk associated with these events. In hospitalized patients, hypoglycemia has distinct precipitating factors, including fasting, interruption of nutritional support, and acute kidney injury, and is associated not only with in-hospital mortality and prolonged length of stay but also with readmission and mortality after discharge. The potential clinical benefit of preventing hypoglycemia may therefore be particularly large in these populations. This does not imply uniform relaxation of glycemic targets, but rather an individualized approach in which patients at high risk are identified in advance and prioritized for clinical attention. A practical starting point is assessment of hypoglycemia history, current glucoselowering therapy, renal function, and cognitive and functional status.